Mycovia Pharmaceuticals Announces Partnership with Gedeon Richter to Commercialize and Manufacture VT-1161 for Recurrent Vulvovaginal Candidiasis
Agreement expands Mycovia’s global commercialization plans for VT-1161 to Europe, Latin America, Australia, Russia and Commonwealth of Independent States
Mycovia continues to rapidly develop VT-1161 as a potential first FDA-approved treatment of recurrent vulvovaginal candidiasis
Durham, N.C. – October 16, 2019 – Mycovia Pharmaceuticals, Inc. today announced it has entered into an exclusive license and development and technology transfer agreement with Gedeon Richter Plc., based in Budapest, Hungary, to commercialize and manufacture VT-1161 in Europe, Latin America, Australia, Russia and other CIS countries. VT-1161, an oral antifungal product candidate, is currently in Phase 3 clinical trials for the treatment of Recurrent Vulvovaginal Candidiasis (RVVC), a debilitating, chronic infectious condition that affects nearly 138 million women worldwide each year.